Segall Bryant & Hamill LLC Has $16.17 Million Stake in Halozyme Therapeutics, Inc. $HALO

Segall Bryant & Hamill LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 310,830 shares of the biopharmaceutical company’s stock after selling 32,341 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.25% of Halozyme Therapeutics worth $16,169,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Wealth Preservation Advisors LLC bought a new position in Halozyme Therapeutics in the first quarter valued at approximately $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $33,000. Brooklyn Investment Group boosted its holdings in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 670 shares in the last quarter. CWM LLC increased its stake in shares of Halozyme Therapeutics by 46.3% in the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 438 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth $89,000. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

HALO has been the topic of several research analyst reports. Benchmark raised their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Finally, The Goldman Sachs Group raised their target price on shares of Halozyme Therapeutics from $54.00 to $56.00 and gave the company a “neutral” rating in a research report on Tuesday, November 18th. Seven investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.10.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $70.34 on Friday. The business has a 50 day moving average of $69.63 and a 200-day moving average of $63.55. The company has a market capitalization of $8.27 billion, a P/E ratio of 16.10, a P/E/G ratio of 0.35 and a beta of 1.18. Halozyme Therapeutics, Inc. has a 1 year low of $46.21 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.27 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 2,227 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $50,721,994.47. The trade was a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 110,227 shares of company stock worth $8,028,955 over the last three months. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.